First Time Loading...

Regeneron Pharmaceuticals Inc
NASDAQ:REGN

Watchlist Manager
Regeneron Pharmaceuticals Inc Logo
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
Watchlist
Price: 957 USD 3.57% Market Closed
Updated: May 4, 2024
Section:
 

Relative Value

The Relative Value of one REGN stock under the Base Case scenario is 590.56 USD. Compared to the current market price of 957 USD, Regeneron Pharmaceuticals Inc is Overvalued by 38%.

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

REGN Relative Value
Base Case
590.56 USD
Overvaluation 38%
Relative Value
Price
Worst Case
Base Case
Best Case

Valuation Multiples

8
P/S
P/S
Price to Sales
8
vs History
12
vs Industry
54
Median 3Y
6
Median 5Y
6.1
Industry
8.3
Forward
7.4
More Details
26.5
P/E
P/E
Price to Earnings
26.5
vs History
6
vs Industry
7
Median 3Y
15.4
Median 5Y
17.4
Industry
26.8
Forward
21.1
More Details
22.8
P/OCF
P/OCF
Price to OCF
22.8
vs History
20
vs Industry
8
Median 3Y
16.9
Median 5Y
17.1
Industry
23.3
More Details
29.1
P/FCFE
P/FCFE
Price to FCFE
29.1
vs History
17
vs Industry
5
Median 3Y
24.9
Median 5Y
20
Industry
21.4
More Details
4
P/B
P/B
Price to Book Value
4
vs History
41
vs Industry
25
Median 3Y
3.7
Median 5Y
3.8
Industry
2.6
More Details
6.3
EV/S
EV/S
Enterprise Value to Sales
6.3
vs History
33
vs Industry
51
Median 3Y
5.7
Median 5Y
5.7
Industry
7.5
Forward
5.8
More Details
7.3
EV/GP
EV/GP
Enterprise Value to Gross Profit
7.3
vs History
31
vs Industry
49
Median 3Y
6.6
Median 5Y
6.6
Industry
9.2
More Details
17.8
EV/EBITDA
EV/EBITDA
Enterprise Value to EBITDA
17.8
vs History
20
vs Industry
7
Median 3Y
11.8
Median 5Y
14.2
Industry
4.5
Forward
14.5
More Details
19.6
EV/EBIT
EV/EBIT
Enterprise Value to EBIT
19.6
vs History
17
vs Industry
7
Median 3Y
12.5
Median 5Y
15.4
Industry
4.4
Forward
15.5
More Details
18.1
EV/OCF
EV/OCF
Enterprise Value to OCF
18.1
vs History
39
vs Industry
9
Median 3Y
15.6
Median 5Y
16
Industry
5.6
More Details
22.6
EV/FCFF
EV/FCFF
Enterprise Value to FCFF
22.6
vs History
47
vs Industry
7
Median 3Y
21.1
Median 5Y
21.8
Industry
3.4
More Details
19.3
EV/IC
EV/IC
Enterprise Value to IC
19.3
vs History
4
vs Industry
15
Median 3Y
3.7
Median 5Y
3.8
Industry
5
More Details

Multiples Across Competitors

REGN Competitors Multiples
Regeneron Pharmaceuticals Inc Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
All Countries
All Countries
Close
Market Cap P/S P/E EV/EBITDA EV/EBIT
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
104.7B USD 8 26.5 17.8 19.6
US
Abbvie Inc
NYSE:ABBV
289.2B USD 5.3 60 13 19.9
US
Amgen Inc
NASDAQ:AMGN
166.7B USD 5.9 24.8 17.9 26.8
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
103.4B USD 10.5 28.6 22.8 23.9
AU
CSL Ltd
ASX:CSL
133.2B AUD 6.2 35.6 21.6 26.7
US
Gilead Sciences Inc
NASDAQ:GILD
80.7B USD 2.9 166.8 6.7 8.8
US
Moderna Inc
NASDAQ:MRNA
47.8B USD 7 -10.1 -11 -9.4
US
Seagen Inc
NASDAQ:SGEN
43.1B USD 18.8 -57.5 -61.9 -55.8
US
Biogen Inc
NASDAQ:BIIB
31.7B USD 3.3 27.1 13.9 17.4
KR
Celltrion Inc
KRX:068270
39.2T KRW 18 73.1 44.7 61.6
IE
Horizon Therapeutics PLC
NASDAQ:HZNP
26.6B USD 7.3 60.8 27.9 47

See Also

Summary
REGN intrinsic value, competitors valuation, and company profile.
DCF Valuation
REGN stock valuation using Discount Cash Flow valuation method.
Relative Valuation
REGN stock valuation using valuation multiples.
Wall Street Estimates
REGN price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
REGN stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
ALPHA SPREAD
Join more than 134,100+ value investors using Alpha Spread
Create a free account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2024 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.